# A New Hematological Prognostic Index For Covid-19 Severity

Abdulmajeed A. Hammadi<sup>1</sup>, Adnan M. Al Jubouri<sup>2</sup>, Ghassan Ahmed<sup>1</sup>, Ali H. Hayyawi<sup>1</sup>, Khalil Kareem<sup>1</sup>, Faiq I. Gorial<sup>2</sup>, Muhammed Waheeb Salman<sup>2</sup>, Mohammed Ghanim<sup>3</sup>, Basil F. Jameel<sup>3</sup>, Ali M. Jawad<sup>2</sup>, Hassan M. Abbas<sup>3</sup>, Ali A. Al-Gharawi<sup>3</sup>, Jawad I Al-shareef<sup>3</sup>, Kawthar F. Nasser<sup>3</sup>, Mohammad Y. Abdulrazaq<sup>4</sup>

1 Alyermouk Teaching Hospital.

2 College of Medicine, University of Baghdad, Medical City Teaching Complex.

3 Medical City Teaching Complex.

4 National Tuberculosis Institute.

#### Abstract

**Background:** severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or Covid-19 is a nationwide public health emergency with significant impact on human life.

**Objective:** To develop a new simple hematological prognostic index for Covid-19 severity state.

**Patients and methods**: This observational cross sectional study was conducted on 250 patients with Covid-19 disease. Age , gender, and severity of Covid -19 were recorded. Complete blood count and lactate dehydrogenase were measured.

New index: COVID-19 severity-Iraqi-index = CSI index to predict COVID-19 severity.

CSI index is monocyte/lymphocyte absolute counts multiplied by LDH (lactate dehydrogenase)/upper normal reference laboratory range of LDH value.

**Results:** Mean age of patients was 50.4 + 15.1 years. Majority of patients were Males 148 (59.2%)..Most of patients were in stage 2 and 3 (> 94%). There was a significant difference between means of White Blood Cells, lymphocytes and Monocytes among the different stages of the disease (P = 0.0001, 0.036, 0.012). There was a significant moderate correlation between the prognostic index and the stage of the disease (r=0.41, p=0.0001).

**Conclusions:** CSI index is a new simple predictor of clinical outcome in patients with covid-19 during early stage of the disease.

Keywords: SARS-COV2, Prognosis, severity, COVID-19

#### Introduction

Severe acute respiratory syndrome corona virus 2 (SARSCov2) or corona virus 19 COVID 19) pandemic infects more than 50 million people globally with mortality of more than one million all over the world till now. The World Health Organization declared Covid-19 as a pandemic on 11 March 2020. It is reported that around 10 % of the patients progressed toward critical illness (1-3).

Covid -19 is a clinical spectrum of illness ranging from mild form with upper respiratory symptoms including loss of sense of smell or taste to moderate condition with fever and pneumonia to severe lung infiltrations with respiratory failure (4). Many studies pointed to prognostic indices related to variety of factors including: older age, chronic diseases, impaired immunity and many biomarkers like serum ferritin, D dimer, serum lactate dehydrogenase, lymphopenia, albumen level, C reactive protein, procalcitonin and others(5-8).

Since the covid-19 pandemic impacts a pressure on intensive care facilities, it would be important to stratify patients' admission to those critical care units. (6) It is important to know risk factors and biomarkers that predict disease progression at earlier stages to modify treatment

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

protocols. The aim of this study was to develop a new simple hematological prognostic index for Covid-19 severity state.

#### Patients and methods

#### Study design

This analytic cross sectional study was conducted at the covid-19 outpatient specialized clinic or admitted to the isolated ward in the hospital in Al-Yarmouk Teaching Hospital and Baghdad Teaching Hospital from June 2020 to November 2020.

The study was approved by the ethical research committee of Department of Medicine, College of Medicine, University of Baghdad with the No. ERC.DoM.CoM,UoB.Ju.2020.1 with date: of June, 2nd, 2020 and was conducted according to the Declaration of Helsinki and its amendments and the Guidelines for Good Clinical Practices issued by the Committee of Propriety Medicinal Product of the European Union. An informed consent was taken from all participants prior to their inclusion in the study.

# Sample selection

# **Inclusion criteria**

- 1. Patients with age above 16 years and of any gender
- 2. Definite diagnosis of COVID-19 according to the WHO classification criteria (18).
- 18) World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization; 2020
- 3. Patient understands and agrees to comply with planned study procedures
- Severity assessment was based on 4 clinical stages according to (COVID-19) Outbreak in China: Summary of a Report of 72□314 Cases from the Chinese Center for Disease Control and Prevention (1)
- A. Mild Disease: Patients with mild illness may present with symptoms of an upper respiratory tract viral infection. These include dry cough, mild fever, nasal congestion, sore throat, headache, muscle pain, and malaise. It is also characterized by the absence of serious symptoms such as dyspnea. The majority (81%) of COVID-19 cases are mild in severity. Furthermore, radiograph features are also absent in such cases Patients with mild disease can quickly deteriorate into severe or critical cases.
- B. Moderate Disease: These patients present with respiratory symptoms of cough, shortness of breath, and tachypnea. However, no signs and symptoms of severe disease are present.
- C. Severe Disease: Patients with severe disease present with severe pneumonia. Diagnosis is clinical, and complications can be excluded with the help of radiographic studies. Clinical presentations include the presence of severe dyspnea, tachypnea (respiratory rate > 30/minute), respiratory distress, SpO2  $\leq 93\%$ , PaO2/FiO2 < 300, and/or greater than 50% lung infiltrates within 24 to 48 hours.
- D. Critical disease: In addition, 5% of patients can develop a critical disease with features of respiratory failure, RNAaemia, cardiac injury, septic shock, or multiple organ dysfunctions. Data from the Chinese Centers for Disease Control and Prevention (CDC) suggest that the case fatality rate for critical patients is 49%.

#### **Exclusion criteria**

- 1. Patients refuse to enrol in the study
- 2. Pregnancy

#### Procedure

A new index: COVID-19 severity-Iraqi-index = CSI index was developed. The CSI index is calculated according to the following formula: Monocyte/lymphocyte absolute counts x LDH (lactate dehydrogenase)/upper normal LDH value This new index is the result of 3 main parameters which are the monocyte, lymphocyte count and lactate dehydrogenase which is the main agreed upon enzyme reflecting the disease severity.

**Statistical issue:** data were grouped and analyzed using SPSS v26 program. A comparison of means was performed using ANOVA test for the normally distributed data and Kruskal-Wallis test for variables not follow the normal distribution. A correlation statistic was done to find the correlation coefficient. The median index value for moderate cases was considered as a cutoff value for moderate diseases. The median index value for severe cases was considered as a cutoff value for severe diseases.

#### Results

A total of 250 patients with Covid-19 were included in this study. The mean and standard deviation of the age was 50.4 + 15.1 years with range from 16 year to 85 year. Males were more than female 148(59.2%), 102(40.8%) respectively. The majority of patients were in stage 2 and 3 forming together more than 94% of the study group. Stage 1 mild cases were 4 (1, 6%), Stage 2 moderate cases were 112 (44, 8%), stage 3 severe cases were 124 (49, 6%), and stage 4 critical cases were 10 (4%) (Table-1).

All patients were improved and discharged from the hospital except four cases were dead.

/ariables (N=250)		Frequency	Percent	
Age	e group in years			
	16-30	35	14.0	
	31-45	64	25.6	
	46-60	88	35.2	
	61-85	63	25.2	
Ger	nder	I	I	
	Male	148	59.2	
	Female	102	40.8	
Sta	ges	I	I	
	Stage 1	4	1.6	
	Stage 2	113	45.2	
	Stage 3	123	49.2	
	Stage 4	10	4.0	

**Table 1:** Distribution of the sample according to some variables


Measurement of main blood constituents were done for all the patients including automated blood cell counts and a comparison was made in their level in the four stages of the disease. The results shown in table-2 which revealed a significant difference between means of WBC, lymphocytes, monocytes and hemoglobin among the different stages of the disease (P <0.001, p<0.001, p<0.001), but it was not significant for platelets count (P = 0.732) and monocytes (P = 0.065).

	Stages								
	1		2		3		4		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	P-Value
WBC	5025	1047	7457	3237	11742	7205	14040	7806	<0.001
LYMPH	1980	689	1782	1132	1432	1003	1088	1665	<0.001
MONO	488	202	493	249	704	648	750	727	0.065
Hb	12.05	3.62	12.98	1.88	12.97	1.92	12.32	1.71	<0.001
Platelet	208	39	256	92	256	105	290	158	0.732
s.LDH	208.25	12.23	219.39	45.66	293.47	164.27	488.70	279.33	<0.001
Index	0.26	0.14	0.35	0.23	0.95	1.14	1.85	1.78	< 0.001

Table 2: The mean and standard deviation of blood cell counts and serum lactatedehydrogenase in different stages

Table 3: represented the Spearman's correlation study. There was a significant correlation between the index and the stage of the disease, but the correlation coefficient was moderate one (0.41), the prediction value was 15%.

		Index	Index			
		Median	Mean	Standard Deviation		
	1	0.259	0.26	0.14	0.0001	
Ch	2	0.280	0.35	0.23		
Stage	3	0.600	0.95	1.14	0.0001	
	4	1.550	1.85	1.78		



**Figure 1**: Dot plot represent the regression model between the index and the stage of Covid -19 disease.

#### Discussion

We developed a new simple equation that depends on 3 main important parameters (serum lactate dehydrogenase, lymphocyte absolute count, and monocyte absolute count) to predict clinical outcome for patients with covid-19 (8,9), Our new index: COVID-19 severity-Iraqi-index (CSI).

LDH level serum improves the prediction power of Covid 19 severity. Also absolute lymphocyte count is good prognostic predictor of clinical outcome. Lymphopenia in patients with covid-19 can be explained by 2 mechanisms one of them is redistribution and the other is bone marrow selective lymphocyte suppression/

The new prognostic index of COVID-19 severity (CSI) has a very good correlation to the clinical stage. The higher the index the poorer the clinical outcome (p=<0.001).

We did not find similar index in the available published data regarding covid-19 prognosis. The score can be divided into low, intermediate, and high severity depending on the score number.

Any value for the index below 0.60 were considered as mild cases, while a score of 0.60 was considered as a cutoff point for moderate cases and a score of 1.55 as a cutoff point for severe cases.

This study has some limitations: some Other important parameters that were not included in our study are organ functions, CT scan results, and oxygen saturation because we intended to simplify the test early in the course of the disease. (10)

For instance Zhang et al pointed to the relation of CT chest involvement to many laboratory parameters like granulocyte count, LDH level ,procalcitonin, and C reactive protein.(11)

A clinical correlation also mentioned in relation to progressive lung disease in relation to laboratory findings like lymphocytes, monocytes, platelets, and liver functions. (12)

Others reported relation of clinical outcome and chest CT scan to D-dimer and C reactive protein.(13)

A positive relation also found between CT chest and leucocyte count, neutrophils and interlukin-2. (14, 15)

# Conclusions

COVID-19 severity-Iraqi index is a new simple predictor of clinical outcome in patients with covid-19 during early stage of the disease.

**Contributors**. All authors have contributed to the manuscript in study design, study concept, data collection and interpretation, and final writing and revision of the manuscript.

Funding: None Competing interests None declared

### **References:**

- 1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-42.
- 2. Garcia PD, Fumeaux T, Guerci P, et al. RISC-19-ICU Investigators. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinical Medicine. 2020 Aug 1;25:100449
- 3. World Health Organization. Rolling Updates on Coronavirus Disease (COVID-19). Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen
- 4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223):497-506.
- 5. Zhou F, Yu T, Du R, et al . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020; 395: 1054–1062.
- Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. Jama. 2020 Apr 28;323(16):1545-6.
- 7. Cascella M, Rajnik M, Cuomo A, et al . Features, evaluation and treatment coronavirus (COVID-19). InStatpearls [internet] 2020 Mar 8. StatPearls Publishing.

- Cecconi M, Piovani D, Brunetta E, et al . Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy. Journal of Clinical Medicine. 2020 May;9(5):1548..
- 9. Blackburn R, Zhao H, Pebody R, et al. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004–2015. Clinical Infectious Diseases. 2018 Jun 18;67(1):8-17.
- Royal College of Radiology Position on the Role of CT in Patients Suspected with Covid-19 Infection. Available online: https://www.rcr.ac.uk/college/coronavirus-covid-19-what-rcr-doing/rcr-position-role-ctpatients-suspected-covid-19 (accessed on 24 April 2020).
- 11. Zhang B, Zhang J, Chen H, et al . Novel coronavirus disease 2019 (COVID-19): relationship between chest CT scores and laboratory parameters. European Journal of Nuclear Medicine and Molecular Imaging. 2020 May 12:1.
- 12. Guler E, Unal NG, Cinkooglu A, et al . Correlation of liver-to-spleen ratio, lung CT scores, clinical, and laboratory findings of COVID-19 patients with two consecutive CT scans. Abdominal Radiology. 2020 Oct 13:1-9.
- 13. Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. European radiology. 2020 Dec;30(12):6808-17.
- 14. Hu Y, Zhan C, Chen C, Ai T, Xia L. Chest CT findings related to mortality of patients with COVID-19: A retrospective case-series study. Plos one. 2020 Aug 25;15(8):e0237302.
- Zhang, J., Meng, G., Li, W. et al. Relationship of chest CT score with clinical characteristics of 108 patients hospitalized with COVID-19 in Wuhan, China. Respir Res 21, 180 (2020). https://doi.org/10.1186/s12931-020-01440-x.